

Cost-effectiveness of elranatamab versus current therapies for the management of patients with triple-class exposed, relapsed and refractory multiple myeloma, including other bispecific and physician's choice of treatment in Spain

Cristina Encinas¹, Virginia Lozano², Patrick Hlavacek³, Julia Llinares², Sofía Toribio², David Carcedo⁴, Jordi Asís-Montalt⁴, Joaquín Martínez-López⁵

¹ Hospital General Universitario Gregorio Marañón, Madrid, Spain

² Pfizer SLU, Madrid, Spain

³ Pfizer Inc, New York, NY, USA

⁴ Hygeia Consulting, Madrid, Spain

⁵ Hospital Universitario 12 de Octubre, CNIO, University Complutense, i+12, Madrid, Spain.

Corresponding author: David Carcedo Rodríguez, <david.carcedo@hygeiaconsulting.com>

Supplementary materials

Table S1. Composition of PCT (adapted to Spanish setting [36] from LocoMMotion)

Treatment	Weight in PCT ¹
Carfilzomib, dexamethasone	23.18%
Pomalidomide, cyclophosphamide, dexamethasone	22.50%
Pomalidomide, dexamethasone	19.12%
Bendamustine, bortezomib, dexamethasone	4.74%
Carfilzomib, cyclophosphamide, dexamethasone	4.74%
Lenalidomide, dexamethasone	4.06%
Bortezomib, doxorubicin, dexamethasone	3.38%
Carfilzomib, lenalidomide, dexamethasone	3.38%
Carfilzomib, pomalidomide, dexamethasone	3.38%
Melphalan	3.38%
Belantamab mafodotin ²	2.71%
Bendamustine, prednisone	2.71%
Cyclophosphamide, dexamethasone	2.71%

¹Treatments reported in LocoMMotion with a current negative reimbursement resolution in Spain have not been included and percentages for the rest of treatments have been redistributed; ²The EMA has recently recommended the non-renewal of authorisation of belantamab for MM [46]

Table S2. Adverse events incidence rates (treatment-related grade 3-4 AEs with a reported incidence of 5% or higher in any of the comparators)

AE	Elranatamab	Teclistamab	PCT
General AEs			
Thrombocytopaenia	23.6%	22.4%	17.7%
Anaemia	37.4%	37.6%	10.9%
Neutropenia	48.8%	65.5%	13.3%
Leukopenia	13.0%	9.1%	4.8%
Hypokalaemia	10.6%	4.8%	0.0%
Hypophosphatemia	0.8%	6.1%	0.0%
Lymphopenia	25.2%	34.5%	5.6%
Infection	39.8%	44.8%	6.5%
Hypertension	6.5%	5.5%	0.0%
Renal and urinary disorders	5.7%	4.8%	5.2%
Alanine aminotransferase increased	5.7%	0.0%	0.0%
Sepsis	6.5%	0.0%	0.0%
Special interest AEs			
ICANS (grades 1-2)	3.4%	3.0%	-
ICANS (grades 3-4)	0.0%	0.0%	-
CRS (grades 1-2)	57.7%	71.5%	-
CRS (grades 3-4)	0.0%	0.6%	-

Sources: MagnetisMM-3 initial analysis and extended follow-up [18,26], MajesTEC-1 initial analysis and extended and follow-up [23–25], LocoMMotion results [13]

Table S3. Unit costs

	Unit cost ¹
Treatment acquisition costs (no deductions applied)²	
Elranatamab 44 mg vial (step-up dose)	€2,913.00
Elranatamab 76 mg vial (full dose)	€5,032.00
Teclistamab 30 mg vial (step-up dose)	€905.00
Teclistamab 153 mg vial (full dose)	€4,615.40
Carfilzomib 10 mg vial	€223.17
Dexamethasone 4 mg 30 tablets	€6.14
Pomalidomide 4 mg 21 capsules	€9,300.00
Cylophosphamide 200 mg vial	€5.00
Bendamustine 100 mg 5 vials	€657.15
Bortezomib 2.5 mg vial	€360.56
Lenalidomide 5 mg 21 capsules	€375.84
Doxorubicin 200 mg vial	€54.60
Melphalan 2 mg 50 tablets	€27.44
Belantamab mafodotin 100 mg vial	€6,974.48
Prednisone 30 mg 30 tablets	€2.41
Treatment administration costs	
Oral administration	€0.00
Injection	€150.00
IV administration	€318.00
Adverse event prophylaxis	
Aciclovir (cost per cycle)	€14.07
Intravenous immunoglobulin G (cost per cycle)	€232.88
Adverse event management	
Thrombocytopenia	€755.59
Anaemia	€649.35
Neutropenia	€441.60
Leukopenia	€1,743.43
Hypokalaemia	€281.05
Hypophosphatemia	€281.05
Lymphopenia	€1,743.43
Infection	€2,100.79
Hypertension	€3,008.43
Renal and urinary disorders	€4,513.99
Alanine aminotransferase increased	€623.74
Sepsis	€4,576.67
ICANS/CRS (grades 1-2)	€1,413.87
ICANS/CRS (grades 3-4)	€2,837.37

¹All treatment acquisition costs were obtained from the General Pharmaceutical Council of Spain (CGCOF) database [31]. For drugs with multiple presentations available, only the one considered in the model is included. Treatment administration and AEs management costs were obtained from database eSalud [30]; ²In the base case, mandatory deductions following Royal Decree-law 8/2010 have been used whenever applicable [32].

Figure S1. DoT exponential distribution based on median values reported for elranatamab (a.), teclistamab (b.) and PCT (c.)




Figure S2. OWSA of elranatamab versus teclistamab




Figure S3. OWSA of elranatamab versus treatment basket

